Quantinno Capital Management LP Increases Stake in Genmab A/S Sponsored ADR $GMAB

Posted by George Bondi on Aug 6th, 2026

Quantinno Capital Management LP lifted its position in Genmab A/S Sponsored ADR (NASDAQ:GMAB – Free Report) by 14.4% in the 1st quarter, Holdings Channel.com reports. The fund owned 282,498 shares of the company’s stock after acquiring an additional 35,588 shares during the period. Quantinno Capital Management LP’s holdings in Genmab A/S were worth $7,579,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. CIBC Private Wealth Group LLC grew its holdings in Genmab A/S by 291.9% during the 4th quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock valued at $25,000 after purchasing an additional 616 shares during the last quarter. NewEdge Advisors LLC lifted its stake in Genmab A/S by 1,229.0% in the third quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock worth $38,000 after purchasing an additional 1,143 shares during the last quarter. V Square Quantitative Management LLC bought a new stake in Genmab A/S in the first quarter worth about $34,000. Brown Brothers Harriman & Co. boosted its position in shares of Genmab A/S by 143.4% during the third quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock valued at $41,000 after buying an additional 780 shares during the period. Finally, Osaic Holdings Inc. boosted its position in shares of Genmab A/S by 37.8% during the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after buying an additional 440 shares during the period. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Stock Up 0.8%

Shares of NASDAQ:GMAB opened at $29.26 on Thursday. Genmab A/S Sponsored ADR has a 52-week low of $21.00 and a 52-week high of $35.43. The stock has a market cap of $18.24 billion, a P/E ratio of 22.17, a price-to-earnings-growth ratio of 1.82 and a beta of 0.83. The business’s 50 day moving average is $27.16 and its 200 day moving average is $28.01. The company has a quick ratio of 2.17, a current ratio of 2.18 and a debt-to-equity ratio of 0.87.

Analyst Ratings Changes

GMAB has been the topic of several recent analyst reports. New Street Research set a $43.00 price target on Genmab A/S in a report on Wednesday, July 22nd. Truist Financial began coverage on Genmab A/S in a report on Wednesday, May 27th. They set a “buy” rating and a $40.00 price objective for the company. TD Cowen raised Genmab A/S from a “hold” rating to a “buy” rating and upped their price objective for the company from $32.00 to $43.00 in a research report on Wednesday, July 22nd. HC Wainwright increased their target price on Genmab A/S from $38.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, July 2nd. Finally, The Goldman Sachs Group upgraded Genmab A/S from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 22nd. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $39.28.

Get Our Latest Research Report on Genmab A/S

Genmab A/S Company Profile

(Free Report)

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.